AKT1 and cancer: In light of the fact that several Akt inhibitors are being developed as anti-cancer drugs [14,15] we elected to evaluate the recently described compound, (3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3Himidazo[4,5-b]pyridin-2-yl)pyridin-2-amine) named Miransertib (ARQ 092).